> Introducing New Divide Ventures
Deploying conviction capital at the intersection of computational biology, novel therapeutics, and deep tech platforms.
The biopharma landscape has shifted. The next decade belongs to founders who leverage computational advantages to compress discovery timelines, not just those with novel biology.
Traditional VCs pattern-match for consensus. We underwrite from first principles. We are built by operators who understand that extraordinary science requires an entirely different kind of institutional partner at the seed stage.
AI/ML-driven target identification and protein design platforms that fundamentally alter the economics of drug discovery.
Next-gen approaches beyond small molecules and mAbs. Gene editing, precision delivery systems, and synthetic biology.
Infrastructure and tooling that enables the industrialization of biology. Lab automation, bio-manufacturing, and regulatory-tech.